Stromal‐immune cell cross talk fundamentally alters the lung microenvironment following tissue insult by Worrell, Julie C. & MacLeod, Megan K.L.
Stromal–immune cell crosstalk fundamentally alters the lung
microenvironment following tissue insult
Julie C. Worrell and
Megan K. L. MacLeod
Institute of Infection, Immunity and Inflam-
mation, University of Glasgow, Glasgow, UK
doi:10.1111/imm.13319
Received 3 December 2020; revised 22
January 2021; accepted 3 February 2021.
*Correspondence: Julie C. Worrell and
Megan K.L. MacLeod, Institute of Infection,
Immunity and Inflammation, University of
Glasgow, B527, SGDB, 120 University Place,
Glasgow G12 8TA, UK. Email:
Julie.Worell@glasgow.ac.uk and
Megan.MacLeod@glasgow.ac.uk
Senior author: Julie C. Worrell
Summary
Communication between stromal and immune cells is essential to main-
tain tissue homeostasis, mount an effective immune response and pro-
mote tissue repair. This ‘crosstalk’ occurs in both the steady state and
following a variety of insults, for example, in response to local injury, at
sites of infection or cancer. What do we mean by crosstalk between cells?
Reciprocal activation and/or regulation occurs between immune and stro-
mal cells, by direct cell contact and indirect mechanisms, including the
release of soluble cytokines. Moving beyond cell-to-cell contact, this
review investigates the complexity of ‘cross-space’ cellular communication.
We highlight different examples of cellular communication by a variety of
lung stromal and immune cells following tissue insults. This review exam-
ines how the ‘geography of the lung microenvironment’ is altered in vari-
ous disease states; more specifically, we investigate how this influences
lung epithelial cells and fibroblasts via their communication with immune
cells and each other.
Keywords: epithelial cells; fibroblasts; lung; stromal–immune cell interac-
tions.
Introduction
The interactions between stromal and immune cells dur-
ing the steady state and in response to disease causing
agents are complex, encompassing a vast network of
interactions and regulatory mechanisms.1,2 Stromal cells,
including epithelial, endothelial cells and fibroblasts, pro-
vide a structural framework that enables haematopoietic
cells to carry out their functions. Stromal cells provide,
however, much more structural support.3,4 Immune cells
(tissue-resident and those carrying out surveillance
around the body) are instructed by resident stromal cells
in their development, survival and function. Interactions
between stromal and immune cells must be tightly
regulated, failure of cell communications can result in
aberrant repair processes, uncontrolled cell growth and
cancer.5
The respiratory epithelium is a ‘front line’ of defence
and is exposed to a variety of atmospheric contaminants
and noxious stimuli including pollution, cigarette smoke,
respiratory microbes and allergens. Epithelial cells are sus-
ceptible to damage in a variety of lung injury models
including the bleomycin model of pulmonary fibrosis, in
partial pneumonectomy and following influenza virus
infection.6–8 Pulmonary fibroblasts respond to environ-
mental signals triggered by injury or infections, and the
controlled accumulation of fibroblasts to sites of inflam-
mation is crucial for effective tissue repair.9,10 Classically,
Abbreviations: ADI, alveolar intermediate differentiation; AM, alveolar macrophage; ATI, alveolar type I epithelial cell; ATII,
alveolar type II epithelial cell; CAFs, cancer-associated fibroblasts; CCL, C-C motif chemokine ligand; CSF, colony-stimulating
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pathic pulmonary fibrosis; KRT5, keratin-5; LCMV-Cl13, lymphocytic choriomeningitis virus Clone 13; LEC, lymphatic endothe-
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fibroblast activation occurs following lung injury leading
to myofibroblast differentiation and expression of alpha-
smooth muscle actin (a-SMA).11 Destruction and aber-
rant remodelling of extracellular matrix (ECM) is a com-
mon pathological feature of several diseases including
pulmonary fibrosis,12 asthma,13 lung cancer14 and chronic
viral infections.10
New technologies can reveal receptor–ligand
interactions and provide a spatial context to
immune–stromal cell communication
Signals delivered by one cell to another via cell surface
molecules require direct cell–cell contact. In protective
immune responses, important interactions of this type
include the killing of infected cells by CD8 T cells via
Fas/FasL interactions.15,16 Direct contact between stromal
and immune cells is also required to maintain lung
homeostasis. For example, inhibitory signals through the
receptor–ligand interaction CD200-CD200R on lung
epithelial cells and alveolar macrophages require physical
proximity and act to encourage a return to the resting
state following infection.17
Paracrine cell–cell communication does not require
direct cell–cell contact but depends on the diffusion of
signalling molecules from one cell to another. Interactions
between immune and stromal cells often occur following
the release of soluble, cell-derived cytokines and chemoki-
nes (e.g. interferon-alpha (IFN-a) and C-X-C motif che-
mokine ligand (CXCL10)). Non-haematopoietic stromal
cells express the cognate receptors for these molecules18
and following tissue injury are capable of inducing bidi-
rectional activation of circulating immune cells via the
production of chemokines, for example CXCL10.
Progress in transcriptomic analysis, including single-cell
RNA-sequencing (scRNA-seq), is increasing the depth of
understanding of cellular crosstalk in homeostasis and in
disease states. Spatial transcriptomics can provide this
information in the context of the tissue microenviron-
ment by monitoring gene expression in intact tissue sec-
tions rather than dissociated cells. Analysis of these data
using tools such as CellPhoneDB19 (~ 900 receptor–ligand
pairs) and CellTalker20 (~ 2000 receptor–ligand pairs)
allows us to interrogate our knowledge and predict recep-
tor–ligand interactions.
Expression of mRNA of receptor/ligand pairs in disso-
ciated tissues is not sufficient to determine cell–cell inter-
actions. The molecules must be localized in the correct
cellular compartment as soluble molecules, such as
cytokines, usually act locally.21 Visualization of interac-
tions or close proximity between neighbouring cells can
be examined using microscopy. Immunofluorescent and
immunohistochemical methods can be combined for pro-
tein detection and in situ hybridization approaches, such
as RNA-scope, used to visualize gene expression. By
adding further spatial context to ligand–receptor interac-
tions, it is possible to attribute functional properties to
cells based on anatomical location. A combination of
these approaches may be ideal to investigate transcrip-
tional profiles of all lung-resident stromal cells and allow
spatial allocation to distinct microenvironmental niches.
For example, studies investigating how the lung response
to injury alters cellular communication22,23 identified a
new subset of endothelial cells capable of communication
with neighbouring alveolar epithelial cells through vascu-
lar endothelial growth factor (VEGF) signalling.23
Transcriptional studies have highlighted that fibroblasts
display ‘positional identity’, with distinct transcriptomes
depending on tissue and within-tissue location.24,25
Importantly, several recent studies in the human and
mouse lung illustrate the switch between stromal–stromal
and stromal–immune cell interactions in disease states.25–
29 Multiple studies also highlight the biological relevance
of profiling of different cell types in adult tissues, demon-
strating how altered cell–cell communication following
infection or disease results in specific ‘networks’ across
space and local microenvironmental niches.22,23,26,30,31
Pulmonary homeostasis and stromal cell
heterogeneity
The lung consists of a diverse population of stromal cells
that act in concert with innate and adaptive immune cells
to maintain and restore pulmonary homeostasis. The
upper respiratory tract is a heterogeneous cellular ecosys-
tem consisting of pseudostratified epithelium that con-
tains multiciliated, mucus-secreting goblet cells, tuft,
neuroendocrine cells and a population of basal cells.32
Secretory and multiciliated cells perform mucociliary
clearance, a self-clearing mechanism that removes inhaled
particles from the upper airways, preventing their transit
to the deeper more distal areas of the lung.33 Low-level
mucus production by the healthy airway forms a protec-
tive layer that is important for both host defence and
immune homeostasis.
In the distal lung, the respiratory bronchi branch into
bronchioles then terminal bronchioles that extend into the
alveolar ducts and alveolar sacs. Within the alveolus, two
morphologically and functionally distinct populations of
epithelial cells are found, alveolar type I (ATI) and type II
(ATII) epithelial cells. Maintenance of the alveolar epithe-
lium during homeostasis and regeneration after lung injury
in vivo are fuelled by the surfactant-producing ATII cells,
which can renew and differentiate into ATI cells, special-
ized for gas exchange.34 A proportion of ATII cells have
higher ‘clonogenic potential’, they form discrete ‘renewal
foci’ often localized within the perivascular regions at the
edge of the lung following injury,35 suggesting these speci-
fic locations within the tissue are ‘hot spots’ for alveolar
renewal. It is unclear whether the proposed ATII cell
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heterogeneity is the result of differences in cell-intrinsic
potential or microenvironmental regulation. The anatomi-
cal location(s) and plasticity of these cells are reviewed and
described in detail by Basil et al.36
Complex multidirectional interactions between ATII
cells and fibroblasts help maintain the alveolar unit. For
example, fibroblasts communicate with endothelial cells
and ATII cells via gaps in the basement membranes and
secretion of growth factors.35 Localization to the alveolar
space is a unique feature of alveolar macrophages (AM).
Their activation is tightly regulated to limit inflammatory
responses by several cell–cell interactions with epithelial
cells. Epithelial cells deliver inhibitory signals to AMs via
CD200–CD200R interactions,17 while interleukin-10 (IL-
10) and avb6-integrin tethered transforming growth fac-
tor-beta (TGF-b) block pathways that lead to inflamma-
tion. Following epithelial injury/loss, numerous
molecules, including IFN-c, IL-1 and TNF-a, drive AM
activation. Macrophages can also communicate with ATII
cells by transmitting anti-inflammatory signals through
gap junctions and secreting cytokines that promote
epithelial cell proliferation.37 This exemplifies cellular
communication across a local environment and is illus-
trated in Figure 1. Critically, each cell relies on healthy
functioning neighbours, with damage altering the beha-
viour of multiple cell types.
Parenchymal lung fibroblasts are located mainly within
the interstitial space, while airway fibroblasts have a pre-
dominantly subepithelial distribution. Heterogeneity of
fibroblasts in the murine and human lung during home-
ostasis and disease is increasingly recognized38–40;
although there is no consensus on fibroblast lineages,
subtypes, biological properties or plasticity. Pulmonary
fibroblast subpopulations differ in surface marker expres-
sion (e.g. presence or absence of Thy1) and have specific
growth characteristics and antigen presentation func-
tions.41 Alterations in cytokine production, lipid content
and cytoskeletal composition have been demon-
strated,11,42,43 suggesting fibroblasts may either be derived
from different cell types, represent different stages of acti-
vation or are influenced by the surrounding milieu. A
recent study by Xie et al.40 defined six mesenchymal cell
types in the normal mouse lung: myofibroblasts, Col13a1
matrix fibroblasts, Col14a1 matrix fibroblasts, lipofibrob-
lasts, mesenchymal progenitors, mesothelial cells and
endothelial cells. Fibroblasts in different tissues may pro-
vide location-specific signalling to neighbouring cells and
positional cues for wound healing and tissue regeneration.
This concept is termed ‘positional memory’.44
Stromal cells display immune effector functions
and have ‘poised immune potential’
Following infection, pulmonary epithelial cells and fibrob-
lasts secrete a wide range of chemokines and cytokines
that can control cell survival, influence proliferation and
participate in the recruitment and activation of immune
cells in the lung. Both cell types express pattern recogni-
tion receptors (PRRs), such as Toll-like receptor (TLRs),
react to stress and secrete antimicrobial peptide media-
tors.45,46 Airway epithelial cells secrete anti-inflammatory
cytokines to facilitate local clearance of apoptotic cells.47
Fibroblasts actively modulate immune cell behaviour by
adjusting either the local cellular or cytokine microenvi-
ronment. For example, fibroblasts amplify and perpetuate
the immune response via constitutive and inducible
expression of C-C and CXC chemokines or inhibit the
recruitment of circulating immune cells to sites of tissue
injury.3 These functions were highlighted by a recent
study by Krausgruber et al.25 where the authors analysed
fibroblasts, epithelial cells and endothelial cells from 12
different tissues in mice in homeostasis and following a
systemic viral infection with LCMV. This study identified
the expression of chemokine genes by stromal cells, for
example Ccl25, Ccl21a, Cxcl10, Cxcl12, Ccl2 and Ccl13,
that function to attract immune cells. Stromal cells
expressed genes encoding ligands and receptors including
B2m, Cd74, Sdc1, Sdc4, Tnfrsf1a and Vcam1, which facil-
itate communication with immune cells such as B cells,
macrophages and T cells.25
In this study, different stromal cell subtypes from the
same organ displayed more transcriptional similarity
among shared ‘immune genes’ than the same stromal
subtypes isolated from different organs, suggesting co-or-
dination of their response.25 Though this study was per-
formed in mice, the alteration of cellular communication
networks from baseline stromal–stromal to stromal–im-
mune interactions in response to viral infection is consis-
tent with findings from Vieira Braga et al.,26 in the
human lung.
Interestingly, Krausgruber et al. suggest some immune
genes expressed by stromal cells have an ‘unrealized
immune potential’ and are ‘poised’ for expression
(ATAC-seq showed chromatin in an open state). ‘Poised’
genes have an open, accessible promoter but with low
levels of gene expression in stromal cells. This indicates
the potential of these genes to facilitate a rapid response
by stromal cells when infection occurs, protecting the
organ in which they reside.25 This was further confirmed
by infection of mice with LCMV; genes with ‘unrealized
potential’ were now expressed in fibroblasts and endothe-
lial cells. However, some key response modules, including
IFNGR1, display high chromatin accessibility across all
samples, suggesting the rapid ability to respond to type 1
IFN is common.25 It should be noted that stromal cells
from mucosal sites (e.g. lung and gut) had very few genes
that displayed ‘unrealized immune potential’, this might
be due to the fact that stromal cells at barrier sites are
constantly exposed to a variety of stimuli and are the
‘first line of defence’.
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Figure 1. Diagram showing stromal–immune cell communication in the upper and distal airways in lung homeostasis and disease. (A) The upper
airways (trachea and main stem bronchi) are lined by a pseudostratified epithelium consisting of secretory (club and goblet), ciliated, tuft and
basal cells. Ciliated cells facilitate the removal of foreign particles and debris via mucociliary clearance (thick red arrow). A layer of stromal
fibroblasts is located beneath the basement membrane. (B) Epithelial cells attempt to clear infections by inducing apoptosis or by dedifferentia-
tion (damaged epithelium shown in red). The epithelium can secrete mucins, and a variety of cytokines and chemokines (solid arrows) that acti-
vate and attract immune cells to the lung. Secreted factors include, but are not limited to, interferon-alpha/beta (IFN-a/b), C-X-C motif
chemokine ligand 8 (CXCL8) and interleukin-1 alpha/beta (IL-1a/b). These factors drive stromal fibroblast proliferation (dotted curly arrows)
and recruit airway macrophages to sites of injury. Airway macrophages and fibroblasts release soluble factors, for example interleukin-13 (IL-13).
Activated T cells in the lung can produce interferon-gamma (IFN-c) and exert their direct effects on macrophages and stromal cells. (C) In the
homeostatic lung, alveolar macrophages (AM) are resident in the alveolar space (blue area) while fibroblasts are found in the interstitium (beige
area). AMs are regulated by the epithelium through their interactions with CD200, expressed by type II alveolar cells (ATII) and transforming
growth factor‑b (TGF-b) tethered to the epithelial cell surface by avb6 integrin, and with secreted interleukin‑10 (IL‑10). (D) In the injured alve-
olus, there is apoptosis or necrosis of the epithelium (AT1 and ATII), denudation of the basement membrane, influx of inflammatory cells and
activation of macrophages, with release of proteases, oxidants (ROS), cytokines and other inflammatory mediators. These factors (solid arrows)
include, but are not limited to, interleukin-6 (IL-6), C-X-C motif chemokine ligand 10 (CXCL10) and interleukin-1 alpha/beta (IL-1a/b). In the
pulmonary interstitium, activated fibroblasts become ECM-producing myofibroblasts, proliferate (dotted curly arrows) and release inflammatory
chemokines IL-6 and C-C motif chemokine ligand 2 (CCL2).
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Recent work from Labarta-Bajo et al.48 found that the
gut epithelial response to LCMV-Cl 13 infection was dri-
ven by IFNAR signalling. Continuous replication of
LCMV-Cl 13 occurred in haematopoietic cells and fibrob-
lasts, but not in the epithelial cells of the intestine. Type
1 IFN signalling, driven by infected haematopoietic cells
and fibroblasts, drove increased intestinal epithelial cell
(IEC) expression of T-cell chemo-attractants, Cxcl9 and
Cxcl10, and promoted recruitment of CD8 T cells.
Further profiling of stromal cell chromatin accessibility
in cells at mucosal sites is needed, particularly in infection
challenge models where it is feasible to compare viral
replication and clearance. Localized lung infection with
respiratory viruses (e.g. influenza) represent a more
organ-specific challenge. ATAC-seq performed prior to,
during and following infection would reveal infection and
immune-driven alterations in interactions between
immune and stromal cells, enabling further characteriza-
tion of the phenomenon of unrealized immune potential.
Lung stromal response to influenza virus
infection
Influenza A virus (IAV) is a common respiratory patho-
gen causing respiratory infections that are a significant
cause of morbidity and mortality worldwide.49,50 The
World Health Organisation (WHO) estimates annual epi-
demics result in about 3 to 5 million cases of severe ill-
ness and about 290 000 to 650 000 respiratory deaths.
The lung contains various heterogeneous populations of
epithelial cells that are altered following IAV infection.
Lost or damaged cells can be replaced by a number of
biological processes. One such process is transdifferentia-
tion in which cells can regress to a point where they can
switch lineages or can directly turn into a distinct cell
type.51 Dedifferentiation of airway cells (e.g. basal cells,
secretory cells, tuft cells) has been observed in several
studies following lung injury,52 indicating a high degree
of cellular plasticity. The differentiation of intrapul-
monary basal-like cells following influenza virus-induced
injury is reviewed extensively here.53 Mice and humans
exhibit dramatic lung regeneration following IAV-induced
injury involving numerous populations of progenitor
cells.54–57 Several studies have employed lineage tracing
strategies; one caveat of this approach is the possibility
that transdifferentiating cells are identified because the
putative originating cell marker is actually an injury-re-
sponsive gene. To avoid inappropriate marking of cell
types, lineage labelling should be performed far in
advance of induced injury and investigate equivalent cell
types in the steady state.
The pulmonary epithelium is immunologically active
and essential for regulating immune responses in the
lung.58 Epithelial dysplasia in mice after infection with
IAV is associated with prolonged inflammation.59,60
Several groups have also identified the presence of inter-
mediate or transitional ATI/ATII cells in the mouse and
human lung following injury.6–8,61 These transitional cell
states are found in response to influenza virus infection,6
in response to bleomycin-induced pulmonary fibrosis and
in recent landmark studies in the lungs of idiopathic
pulmonary fibrosis (IPF) patients.62,63 Choi et al.61 iden-
tified alterations in communication between ‘transitional’
epithelial cells and macrophages following acute lung
injury. Interstitial macrophages were present in larger
numbers post-injury and were adjacent to lung ATII
cells. These macrophages serve as a major producer of
IL-1b, which promoted growth of alveolar (ATII) orga-
noids in vitro.61 Similar findings were observed by Kat-
sura et al.,64 following IAV infection, whereby immune-
derived inflammatory cytokines, IL-1 and TNF-a,
released from inflamed areas serve as a facultative ‘in-
flammation-associated niche’, driving proliferation of
ATII cells.
The function and behaviour of fibroblasts are regulated
both by biochemical and by physical cues.65 IAV infection
can cause abnormal remodelling of lung parenchyma
depending on the severity of infection.59 The pulmonary
ECM continuously provides cells with tightly chore-
ographed spatiotemporal changes in biochemical and bio-
physical signals to regulate tissue-specific cell functions
and fate. Additionally, the ECM is itself a reservoir for
numerous growth factors and cytokines, which are crucial
for cell differentiation and proliferation.66 During infec-
tion, lung fibroblasts respond to damaged epithelial cells,
transmit inflammatory signals and modify the ECM to
generate a tissue environment promoting immune
responses to infection.
A study by Boyd et al.10 identified two subsets of
inflammatory fibroblasts, interferon-responsive fibroblasts
that peak around day 3 post-infection and damage-re-
sponsive fibroblasts that peak around day 12. At day 10
post-infection, when anti-IAV T-cell responses peak,
damage-responsive fibroblasts, expressing the metallopro-
teinase, ADAMTS4, were found in areas of interstitial
inflammation at distal airways.67 The presence of the
ECM protease ADAMTS4 resulted in increased migration
of CD8+ T cells across versican-coated membranes in a
Transwell assay and was associated with increased disease
in vivo. By modifying the extracellular matrix, fibroblasts
can influence the migration of immune cells that enter
inflamed tissues, and, at least in this study, demonstrate
immune and stromal cells collaborating to amplify
immunopathology. Interestingly, ADAMTS4 is also
enriched in the fibrotic human lung.63
In the absence of fibroblast-derived ADAMTS4, fewer
CD8+ T cells were present in the lung and versican levels
were higher.10 This agrees with several studies demon-
strating that versican can suppress cytotoxic T-cell
responses and inhibit migration.68,69 Cancer-associated
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fibroblasts (CAFs) can perform a similar function.5
Immunomodulatory CAFs found in breast cancer can
regulate the migration of T cells and limit their cytotoxic
functions; notably, patients with low levels of these CAF
cells had a survival advantage.70 Figure 2 illustrates how
fibroblast modification of the ECM regulates T-cell
migration.
The ageing process can impact the lung microenviron-
ment. A recent study by Goplen et al.71 showed the aged





































Figure 2. Fibroblast modification of the ECM regulates T-cell entry into the lung in IAV infection and cancer. (A) Following IAV infection,
ECM modified by fibroblast activity integrates innate immune signals to regulate the adaptive immune environment of the lung. Fibroblasts pro-
duce inflammatory chemokines and cytokines that drive ATII proliferation, for example interleukin-1 beta (IL-1b) and tumour necrosis factor-al-
pha (TNF-a). ECM protease-producing fibroblasts degrade the ECM allowing T cells to migrate from the vasculature into the lung tissue to
combat infection. Components are labelled with dotted line arrows. (B) Cancer-associated fibroblasts (CAFs) also modify the ECM and regulate
T-cell entry into the tumour microenvironment. Inflammatory CAF (iCAF) subtypes secrete numerous chemokines and cytokines (indicated by
curly arrows), such as transforming growth factor-b (TGF-b), interleukin-6 (IL-6), interleukin-1 (IL-1) and lymphocyte inhibitory factor (LIF)
that promote the growth and proliferation of tumour cells. Other soluble factors released by iCAFs such as C-X motif chemokine ligand 12
(CXCL12) and vascular endothelial growth factor A (VEGFA) inhibit (blunted arrow) the antitumour immune response via suppression of cyto-
toxic CD8 T cells. Finally, CAFs can synthesize ECM components (MMPs and collagens), and modification of the ECM by IL-6 and C-C motif
chemokine ligand 2 (CCL2) contributes to increased ECM stiffness, which in turn reduces (blunted arrow) the infiltration of effector T cells to
the tumour site. NSCLC, non-small-cell lung cancer.
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increased tissue damage following IAV. Excessive accumu-
lation of tissue-resident influenza-specific, memory CD8
T cells (TRM) occurred in the parenchyma of the aged
lung. CD8 TRM cells require TGF-b during development
and to persist. In aged lungs, elevated TGF-b levels were
accompanied histologically by chronic inflammation and
by fibrotic sequelae after viral pneumonia.71 A possible
explanation for these findings is that a net gain in lung
TGF-b levels, as seen with ageing, may act on lung
parenchymal fibroblasts, to promote the production of
collagen and amplify the fibrotic phenotype.
Specialized microenvironments in the infected
lung: friends or foes?
Lung macrophage infection by the bacteria Mycobacterium
tuberculosis (M.tb) drives a localized inflammatory
response, inducing chemokine secretion, and promotes
recruitment of macrophages, neutrophils and T cells.72
These cells form an organized structure called a granu-
loma. Later, T and B cells surround the granuloma and
are further enclosed by fibroblasts, demarcating the
peripheral structure and perhaps containing the infec-
tion.73 In the M.tb-infected lung, alveolar macrophages,
bronchial epithelial cells and fibroblasts upregulate
expression of ECM-degrading matrix metalloproteinases
(MMPs).74,75 Degradation of the ECM can destabilize the
granuloma. In the human lung, airway epithelial cells and
fibroblasts adjacent to granulomas produce MMP3 in
response to lymphocyte-derived IL-17.76 Expression of
myeloid-derived oncostatin M (OSM) in human granulo-
mas promotes the production of MMP1 and MMP3 by
lung fibroblasts.77 These data indicate that stromal MMP
production promotes tissue destruction, amplifies the
inflammatory response and facilitates the dissemination
of M.tb throughout the lung parenchyma.
Pulmonary viral infection is associated with the forma-
tion of ectopic-inducible bronchus-associated tissue
(iBALT) in the lung.60,78 iBALTs are located in the
perivascular space surrounding large blood vessels and
airways.79 They are an excellent example of a specialized
microenvironment whereby communication between stro-
mal and immune cells promotes immunity. Sites of
iBALT aid robust B- and T-cell responses to influenza
virus and are highly organized, with distinct B-cell folli-
cles and T-cell areas, supporting the proliferation of these
cells.80 It is important to note that organized iBALTs with
distinct T/B zones are only found in the IAV-infected
lungs of young mice and not adult mice, as such, these
findings require cautious interpretation.80,81
Highly specialized stromal cells facilitate organization,
maintenance and survival of leucocytes within iBALT.
CD31+ PNAd+ high endothelial venules (HEV) form near the
outer edges of the B-cell follicle and serve as entry points for
recirculating lymphocytes.82 Lymphatic endothelial cells
(LECs) are found in areas surrounding iBALT and support T-
cell recruitment and survival via secretion of chemokines
(CCL21 and CCL19). In secondary lymphoid organs, mainte-
nance of the B-cell follicle depends on secretion of CXCL13
by CD35+ follicular dendritic cells (FDCs).83 Podoplanin
(PDPN) is a signature molecule of immunomodulatory
fibroblasts.84 Interestingly, a non-classical B-cell follicle has
also been described in iBALT, lacking FDCs, instead using
podoplanin (PDPN)+CD35 CD31 CXCL12+ fibroblast-
like stromal cells to maintain the B-cell area.85 Similar findings
were observed by Denton et al.,86 whereby the production of
CXCL13 by lung fibroblasts induced after IAV infection drives
CXCR5-dependent recruitment of B cells. These PDGRFa+
lung fibroblasts express high levels of podoplanin. Intrigu-
ingly, these CXCL13+ fibroblasts are functionally distinct from
both FDCs and other populations of resident lung fibroblasts,
indicating anatomical location within the lung is an important
driver of immunomodulatory function.
Transcriptionally altered lung epithelial cells are detected
following IAV infection for prolonged periods of time; some
of these cell types appear to be long-lived and express high
levels of immune genes.87,88 Heaton et al. characterized a
long-lived population of club cells, showing increased inter-
feron stimulation that displayed high levels of pro-inflamma-
tory chemokines, Cxcl10, Ccl20 and Ccl5, after viral
clearance.87 This is a model in which infected, surviving club
cells establish a pro-inflammatory environment at the
bronchi, not only promoting increased control of new viral
infections but also contributing to lung pathology. Fiege
et al.88 demonstrate that in addition to club cells, ciliated
epithelial cells, ATI and ATII cells can survive IAV infection.
These surviving cells undergo enhanced proliferation com-
pared with uninfected cells following IAV clearance and
upregulate PD-L1 expression. These cells evade CD8 T-cell-
mediated killing by rapidly clearing viral infection, thus limit-
ing immunopathology. Rane et al.89 demonstrate the appear-
ance of solitary chemosensory cells (SCCs), a type of tuft cell,
in the distal lung following IAV-induced lung injury. These
keratin-5 (Krt5+) cells are located in close proximity to dys-
plastic epithelium and close to inflammatory cells, suggesting
crosstalk between the epithelial and immune compartments.
This may promote inflammation that drives and/or main-
tains epithelial dysplasia. However, these Krt5+ cells rarely
resolve into ATI or ATII cells and instead form dysplastic ‘ep-
ithelial scars’ that persist through the life span of mice.55,56
As they do not contribute to lung function, it is possible they
represent areas of localized fibrosis. Replacing pulmonary
alveoli with scar tissue has long-term functional and physio-
logical consequences for the lung.59,90–92
Pulmonary fibrosis promotes stromal–immune
cell interactions
Lung remodelling eventually leads to resolution of injury
and repair. If this fails or the process becomes self-
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sustaining, uncontrolled tissue fibrosis can occur. Progres-
sive tissue fibrosis leads to disruption of cellular architec-
ture, loss of organ function and eventually death.
Idiopathic pulmonary fibrosis is a chronic progressive
form of interstitial lung disease, characterized pathologi-
cally by heterogeneous areas of inflammation and fibrosis
in the lung.93 A prevailing theory in IPF, broadly applica-
ble to mouse models of lung fibrosis, is that the alveolar
epithelial cell is the initial site of insult/injury. Mecha-
nisms of pulmonary fibrosis are reviewed extensively
here.94
In the bleomycin model of pulmonary fibrosis, Strunz
et al.7 identified a unique transitional cell state (Krt8+ alveo-
lar differentiation intermediate state (ADI)) with a unique
transcriptional signature. This included a p53-driven gene
programme and features of cellular senescence, preceding
the regeneration of ATI cells. These findings are supported
by Kobayashi et al.,8 who identified alveolar epithelial cells
that undergo exhaustive stretching during transdifferentia-
tion that makes them vulnerable to DNA damage and dis-
play enrichment of binding sites for transcription factors,
including TP53, ETS1, NF1, ATF3 and SOX4. Strunz et al.7
demonstrated ADI expression of profibrogenic factors and a
distinct connectome of receptor–ligand pairs, between
endothelial cells, fibroblasts and macrophages in infected
compared with na€ıve mice. These Krt8+ ADI cells form a
unique cellular niche during the fibrogenic phase of tissue
repair, concurrent with myofibroblasts and M2 macro-
phages, displaying differences in communication with these
cell types and the alveolar epithelium.
Reyfman et al.95 identified profibrotic macrophages in
lungs of humans and mice with pulmonary fibrosis. The
existence of these profibrotic macrophages was validated
by recent landmark studies in the IPF lung.62,63
Adams et al.62 showed that profibrotic macrophages were
elevated in the IPF lung; these cells express SPP1, and as dis-
ease progresses, ECM remodelling genes are elevated
(SPARC, GPC4, PALLD, CTSK and MMP9). During late
stage disease, these profibrotic macrophages start expressing
colony-stimulating factor (CSF1), indicating a possible auto-
crine feedback loop for recruitment and activation. Macro-
phages usually provide tropic factors to fibroblasts in return
for survival cues; typically, fibroblasts produce CSF1; and
the CSF receptor (CSFR) is exclusively expressed by macro-
phages. Zhou et al.,96 identified CSF1-CSF1R as the minimal
interaction necessary to sustain fibroblast/macrophage cir-
cuitry in vivo. In this study, the presence of high levels of
CSF1 promoted macrophage growth. A study by Joshi
et al.97 identified M-CSF/M-CSFR signalling in monocyte-
derived alveolar macrophages as a critical regulator of the
fibrotic niche. These macrophages were specifically localized
to fibrotic regions in the proximity of lung fibroblasts and
expressed molecules known to drive fibroblast proliferation,
such as PDGFA. This suggests additional signalling increases
the fibrotic milieu.
Transcriptionally distinct fibroblast subtypes have been
identified, in distinct regions of the fibrotic lung. Myofibrob-
lasts are found in subepithelial regions around airways and
areas of cystic remodelling, while HAS1hi (hyaluronan syn-
thase 1) fibroblasts are restricted to the immediate subpleu-
ral region.63 In contrast, PLIN2+ (perilipin-2) and other
LUM+ (lumican) fibroblasts are found diffusely in
parenchymal regions. Consideration of the spatial location
of these altered cells within the lung confirms the impor-
tance of matching transcriptional signatures with discrete
anatomical locations. However, it is not possible to deter-
mine conclusively whether the fibroblast subsets identified
here represent either phenotypically distinct populations or
a continuum of activation states.
Cellular interactions within IPF lungs were investigated
through analysis of receptor–ligand pairs. This revealed
that dominant interactions were between aberrant basa-
loid cells, fibroblasts, myofibroblasts and T cells.62 The
functional capabilities of these cells and their distinct
contribution to the lung microenvironment require fur-
ther investigation. It is important to consider that in
these studies,62,63 the healthy/control human lung has
been rejected for transplant and may exhibit inflamma-
tion. Additionally, these ‘control’ lungs are likely to have
experienced acute injury, infection and/or previous envi-
ronmental exposures.
The COVID-19 cytokine storm: do myeloid-
derived cytokines drive the activation of stromal
cells?
The mechanism by which severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) causes lung damage
has yet to be fully elucidated. SARS-CoV-2 infection does
closely resemble that of SARS-CoV infection, with aggres-
sive inflammatory responses strongly implicated in caus-
ing damage to the airways.98 Disease severity in patients
is likely a consequence of a combination of viral infection
and host response; the pathophysiology of COVID-19 is
reviewed here.99 Importantly, interactions between
immune and epithelial cells correlate with disease sever-
ity.100 Enhanced plasma concentrations of TNFSF14, EN-
RAGE and OSM correlate with disease severity; the recep-
tors for these myeloid-derived cytokines are highly
expressed by human lung fibroblasts and are implicated
in fibrotic remodelling of the lung.101 It is plausible that
these myeloid-derived cytokines activate the lung stromal
microenvironment. Taken together, these findings indi-
cate stromal–immune interactions are likely more pro-
nounced in severe COVID-19 patients and may
ultimately lead to end-stage organ damage.
Understanding the long-term consequences for the
virally infected lung is of critical importance and could
underlie the distinct severity of responses observed in
COVID-19 patients. We need to ascertain therefore
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whether past infections have consequences for future
immune responses via changes to the stromal cells.
Altered stromal cells may provide immune protection
directly, for example via antiviral cytokine or generate
protective immunity through communication with CD4
and/or CD8 T cells or B cells. Conversely, the expression
of ‘immune genes’ by stromal cells may promote inflam-
mation causing tissue destruction. More in-depth and
temporal analysis of stromal–immune crosstalk is
required to reveal the mechanisms that underlie these
protective or pathogenic interactions.
Conclusions
Cellular communication between immune and stromal
cells in the lung regulates a diverse range of biological
process. Stromal cells can perform functions classically
attributed to immune cells, providing immunomodula-
tory functions and educating local immune cells within
the lung. Inflammatory fibroblasts can integrate danger
signals from epithelial cells and resident immune cells to
produce diverse inflammatory cytokines, ECM compo-
nents and degradative enzymes that modify the local tis-
sue environment. This illustrates that communication
between immune and stromal cells is bidirectional, pro-
viding mutual support for the persistence of both cell
types. Regenerative cues from both the stromal and
immune compartments regulate epithelial repair spanning
vast areas of the lung, and immune cell recruitment to
sites of injury is tightly regulated via local modulation of
ECM. Further elucidation of these context-dependent
interactions may provide us with novel strategies to limit
excessive inflammation and maintain the normal architec-
ture of the lung following tissue injury.
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